516 related articles for article (PubMed ID: 12120876)
1. In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol.
Ungheri D; Albini E; Belluco G
J Chemother; 2002 Jun; 14(3):237-40. PubMed ID: 12120876
[TBL] [Abstract][Full Text] [Related]
2. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
[TBL] [Abstract][Full Text] [Related]
3. [Fosfomycin: an underrated antibiotic for urinary tract infections due to Escherichia coli].
Garau M; Latorre A; Alonso-Sanz M
Enferm Infecc Microbiol Clin; 2001 Dec; 19(10):462-6. PubMed ID: 11844449
[TBL] [Abstract][Full Text] [Related]
4. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?
Knottnerus BJ; Nys S; Ter Riet G; Donker G; Geerlings SE; Stobberingh E
J Antimicrob Chemother; 2008 Aug; 62(2):356-9. PubMed ID: 18424789
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain.
Gobernado M; Valdés L; Alós JI; García-Rey C; Dal-Ré R; García-de-Lomas J;
Rev Esp Quimioter; 2007 Mar; 20(1):68-76. PubMed ID: 17530038
[TBL] [Abstract][Full Text] [Related]
6. Experiences in fosfomycin susceptibility testing and resistance mechanism determination in Escherichia coli from urinary tract infections in the UK.
Cottell JL; Webber MA
J Med Microbiol; 2019 Feb; 68(2):161-168. PubMed ID: 30543320
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of Escherichia coli strains isolated from urine samples obtained in mainland China to fosfomycin trometamol and other antibiotics: a 9-year surveillance study (2004-2012).
Lai B; Zheng B; Li Y; Zhu S; Tong Z
BMC Infect Dis; 2014 Feb; 14():66. PubMed ID: 24502648
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
García-Rodríguez JA; Trujillano Martín I; Baquero F; Cisterna R; Gobernado M; Liñares F; Martín-Luengo F; Piédrola G
J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
[TBL] [Abstract][Full Text] [Related]
9. SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.
Tutone M; Bjerklund Johansen TE; Cai T; Mushtaq S; Livermore DM
Int J Antimicrob Agents; 2022 May; 59(5):106574. PubMed ID: 35307561
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
[TBL] [Abstract][Full Text] [Related]
11. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women.
Minassian MA; Lewis DA; Chattopadhyay D; Bovill B; Duckworth GJ; Williams JD
Int J Antimicrob Agents; 1998 Apr; 10(1):39-47. PubMed ID: 9624542
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
13. [Short communication: comparison of susceptibilities of Escherichia coli urinary tract isolates against fosfomycin tromethamine and different antibiotics].
Aykut Arca E; Karabiber N
Mikrobiyol Bul; 2007 Jan; 41(1):115-9. PubMed ID: 17427560
[TBL] [Abstract][Full Text] [Related]
14. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
Garau J
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
[TBL] [Abstract][Full Text] [Related]
15. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Wilson DT; May DB
Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
[TBL] [Abstract][Full Text] [Related]
16. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections.
Ceran N; Mert D; Kocdogan FY; Erdem I; Adalati R; Ozyurek S; Goktas P
J Infect Chemother; 2010 Dec; 16(6):424-30. PubMed ID: 20585969
[TBL] [Abstract][Full Text] [Related]
18. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.
Keating GM
Drugs; 2013 Nov; 73(17):1951-66. PubMed ID: 24202878
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited.
Kahlmeter G; Poulsen HO
Int J Antimicrob Agents; 2012 Jan; 39(1):45-51. PubMed ID: 22055529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
